Research ArticlesRetracted: Convulsant activity and pharmacokinetic–pharmacodynamic modeling of the electroencephalogram effect of gemifloxacin in rats
References (0)
Cited by (2)
Reversed phase liquid chromatography method with fluorescence detection of gemifloxacin in rat plasma and its application to the pharmacokinetic study
2011, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesCitation Excerpt :GEM (R, S)-7(3-aminomethyl-4-syn-methoxyimino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4 dihydro-4-oxo-1,2 naphthyridine-3-carboxylic acid) is a new fluoroquinolone developed as antibacterial agent with a broad spectrum of activity against Gram-positive and Gram-negative organisms (Fig. 1a). Also, this compound has enhanced activity against other pathogens involved in respiratory tract infections, including Haemophilus influenza and Moraxella catarrhalis [1–4]. It is the only fluoroquinolone in its dual targeting capacity to inhibit both topoisomerase IV and gyrase sites at the therapeutically achievable drug concentrations, whereas older compounds preferentially target topoisomerase IV [5,6].
Acute and twenty-eight days repeated oral dose toxicity study of besifloxacin in Wistar albino rats
2011, Environmental Toxicology and PharmacologyCitation Excerpt :Such effects include gastro intestinal (GI), central nervous system (CNS), phototoxicity, erosion of weight bearing joint and skin or coetaneous events (Mandell and Tillotson, 2002). Fluoroqunolones are analogous of the basic structure of quinoline or naphthyridine ring, and distinct antimicrobial and pharmacological activities observed for each modification in the molecular structure (Mandell and Tillotson, 2002; Roy et al., 2010a). Besifloxacin, {7-[(3R)-3-aminohexahydro-1H-azepin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid} (BOL-303224-A, SS734), is a novel fluoroquinolone antibacterial compound with broad spectrum of activity (Fig. 1).